
Opinion|Videos|May 24, 2024
Key Takeaways from the CARTITUDE-1 and KarMMa Studies
Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Please review data from CARTITUDE-1 that led to the approval of ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM).
- What are some key takeaways for these data?
- Please review data from KarMMa that led to the approval of ide-cel in R/R MM.
- What are some key takeaways from these data?
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
3
Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?
4
Darovasertib Plus Crizotinib Yields 21.1-Month OS in First-Line Uveal Melanoma
5

